<DOC>
	<DOC>NCT00297856</DOC>
	<brief_summary>Pre-licensure studies of GSK Biologicals' Boostrix® have shown it to be generally safe and well-tolerated. This post-licensure study is designed to evaluate relatively uncommon/rare outcomes in a large population cohort. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.</brief_summary>
	<brief_title>Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine</brief_title>
	<detailed_description>Data collection through utilization of automated databases at the study site. The collaborator is Kaiser Permanente Vaccine Study Center.</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects between the age of 10 and 18 years (inclusive) who received a dose of Boostrix and who have safety followup information available</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Boostrix</keyword>
</DOC>